These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26323636)

  • 1. Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications.
    Park SR; Ryu MH; Ryoo BY; Beck MY; Lee IS; Choi MJ; Lee MW; Kang YK
    Cancer Res Treat; 2016 Jan; 48(1):162-70. PubMed ID: 26323636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic Steroid Treatment for Imatinib-Associated Severe Skin Rash in Patients with Gastrointestinal Stromal Tumor: A Phase II Study.
    Kim EJ; Ryu MH; Park SR; Beck MY; Lee WJ; Lee MW; Kang YK
    Oncologist; 2020 Nov; 25(11):e1785-e1793. PubMed ID: 32589310
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs).
    Kim S; Kim HD; Kim EJ; Ryu MH; Kang YK
    BMC Cancer; 2024 Oct; 24(1):1245. PubMed ID: 39379868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Untargeted metabolomics analysis reveals the potential mechanism of imatinib-induced skin rash in patients with gastrointestinal stromal tumor.
    Huang X; Chen L; Liu L; Chen H; Gong Z; Lyu J; Li Y; Jiang Q; Zeng X; Zhang P; Zhou H
    Int Immunopharmacol; 2024 Oct; 140():112728. PubMed ID: 39098227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Case of Disseminated Intra-abdominal Gastrointestinal Stromal Tumor Managed with Low Dose Imatinib.
    Jang BH; Kim BW; Lim KJ; Kim BG; Park SM; Kim JS; Ji JS; Choi H
    Korean J Gastroenterol; 2015 Jun; 65(6):366-9. PubMed ID: 26087692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A safety evaluation of imatinib mesylate in the treatment of gastrointestinal stromal tumor.
    Ben Ami E; Demetri GD
    Expert Opin Drug Saf; 2016; 15(4):571-8. PubMed ID: 26865352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sunitinib-induced reversible purpuric rash in a patient with gastrointestinal stromal tumor.
    Mutlu H; Büyükçelik A; Akça Z; Kaya N
    J Oncol Pharm Pract; 2014 Aug; 20(4):298-301. PubMed ID: 23929730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors.
    Xia Y; Chen S; Luo M; Wu J; Cai S; He Y; Chen X; Zhang X
    Cancer; 2020 May; 126 Suppl 9():2054-2061. PubMed ID: 32293723
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A successful approach to overcome imatinib-induced skin toxicity in a GIST patient.
    Desar IM; van Herpen CM; van Erp NP; Kaal SE; van de Kerkhof PC; van der Graaf WT
    Anticancer Drugs; 2016 Jul; 27(6):576-9. PubMed ID: 26982239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib-associated skin rash is related to treatment outcome in patients with unresectable and/or metastatic gastrointestinal stromal tumor.
    Zhang M; Li L; Sun H; Tang T; Li Q; Chen L; Chen W
    J Gastrointest Oncol; 2022 Feb; 13(1):117-125. PubMed ID: 35284105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperpigmentation due to imatinib: A rare case of cutaneous involvement.
    Rehman H; Hakim N; Sugarman R; Seetharamu N; Saif MW
    J Oncol Pharm Pract; 2020 Sep; 26(6):1511-1515. PubMed ID: 32067560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pemphigus foliaceus in a patient with gastrointestinal stromal tumor treated with adjuvant imatinib mesylate.
    Lewis HA; Chen DY; Rosman IS; Picus J; Anadkat MJ
    Dermatol Online J; 2020 Jun; 26(6):. PubMed ID: 32815695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sigmoid Sinus Thrombosis Followed by Splenic Infarction Due to Imatinib Therapy in a Patient with Gastrointestinal Stromal Tumor; Hematological Side Effects of Imatinib.
    Yilmaz H; Demirağ G; Yılmaz A
    J Pharm Pharm Sci; 2021; 24():148-152. PubMed ID: 33784493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) Syndrome Induced by Imatinib.
    Zgolli F; Aouinti I; Charfi O; Badri T; Elaidli S; Kastalli S; Lakhoua G; Zaïem A
    Curr Drug Saf; 2019; 14(2):151-154. PubMed ID: 30706827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms in angiogenesis-related genes are associated with worse progression-free survival of patients with advanced gastrointestinal stromal tumours treated with imatinib.
    Verboom MC; Kloth JSL; Swen JJ; van der Straaten T; Bovée JVMG; Sleijfer S; Reyners AKL; Mathijssen RHJ; Guchelaar HJ; Steeghs N; Gelderblom H
    Eur J Cancer; 2017 Nov; 86():226-232. PubMed ID: 29054076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Slow desensitization of imatinib-induced nonimmediate reactions and dynamic changes of drug-specific CD4
    Klaewsongkram J; Thantiworasit P; Sodsai P; Buranapraditkun S; Mongkolpathumrat P
    Ann Allergy Asthma Immunol; 2016 Nov; 117(5):514-519. PubMed ID: 27788881
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Role of Surgery in Metastatic Gastrointestinal Stromal Tumors.
    Keung EZ; Fairweather M; Raut CP
    Curr Treat Options Oncol; 2016 Feb; 17(2):8. PubMed ID: 26820287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Wu X; Li J; Xu W; Gao J; Li Y; Shen L
    Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.